HIV

ImmunityBio’s Promising Preclinical HIV Drug is Moving into Phase I Trials
ImmunityBio’s Promising Preclinical HIV Drug is Moving into Phase I Trials
BioSpace
ImmunityBio
HIV
clinical trials
N-803
Flag link:
GSK sub’s injectable outperforms Gilead in late-stage PrEP trial
GSK sub’s injectable outperforms Gilead in late-stage PrEP trial
Endpoints
GSK
Gilead Sciences
HIV
PrEP
Truvada
ViiV Healthcare
cabotegravir
Flag link:
More threat to Gilead's HIV business? GlaxoSmithKline touts long-acting injectable PrEP win against Truvada
More threat to Gilead's HIV business? GlaxoSmithKline touts long-acting injectable PrEP win against Truvada
Fierce Pharma
GSK
Gilead Sciences
Truvada
cabotegravir
HIV
PrEP
Flag link:
Gilead charges CDC with contract breach on HIV research
Gilead charges CDC with contract breach on HIV research
Seeking Alpha
Gilead Sciences
CDC
patents
lawsuits
HIV
R&D
Flag link:
HIV And Flu Drugs Prove Futile In Fight Against Coronavirus
HIV And Flu Drugs Prove Futile In Fight Against Coronavirus
Forbes
China
clinical trials
HIV
Kaletra
Arbidol
COVID-19
Flag link:
J&J HIV drug already in Covid-19 clinical trials flunks in vitro study
J&J HIV drug already in Covid-19 clinical trials flunks in vitro study
MedCity News
JNJ
COVID-19
clinical trials
Prezista
HIV
Flag link:
ACC: Amgen's Repatha cuts cholesterol in rarely studied HIV patients
ACC: Amgen's Repatha cuts cholesterol in rarely studied HIV patients
Fierce Pharma
ACC
Repatha
HIV
clinical trials
Amgen
Flag link:
AbbVie gives up patent rights to HIV med Kaletra amid COVID-19 tests: report
AbbVie gives up patent rights to HIV med Kaletra amid COVID-19 tests: report
Fierce Pharma
AbbVie
HIV
Kaletra
patents
COVID-19
Flag link:
J&J warns doctors not to count on Prezista as a COVID-19 treatment
J&J warns doctors not to count on Prezista as a COVID-19 treatment
Fierce Pharma
COVID-19
coronaviruses
Prezista
HIV
JNJ
Flag link:
ViiV, UNC-Chapel Hill renew HIV partnership for another five years
ViiV, UNC-Chapel Hill renew HIV partnership for another five years
Pharma Times
HIV
ViiV
UNC-Chapel Hill
Flag link:
AbbVie to Test HIV Drug as a Potential Coronavirus Treatment
AbbVie to Test HIV Drug as a Potential Coronavirus Treatment
Motley Fool
AbbVie
Kaletra
COVID-19
coronaviruses
HIV
Flag link:
Gilead's Descovy not worth the higher price over forthcoming Truvada generics: study
Gilead's Descovy not worth the higher price over forthcoming Truvada generics: study
Fierce Pharma
Gilead Sciences
Descovy
Truvada
HIV
drug pricing
Flag link:
GSK's ViiV touts 2-month HIV data as sister injection Cabenuva awaits FDA redemption
GSK's ViiV touts 2-month HIV data as sister injection Cabenuva awaits FDA redemption
Fierce Pharma
HIV
FDA
GSK
Cabenuva
ViiV
Flag link:
Where Will Gilead Sciences Be in 10 Years?
Where Will Gilead Sciences Be in 10 Years?
Motley Fool
Gilead Sciences
HIV
hepatitis C
Flag link:
Gilead loses again in PrEP patent fight with HHS, sending dispute to federal court
Gilead loses again in PrEP patent fight with HHS, sending dispute to federal court
Fierce Pharma
Gilead Sciences
PrEP
HHS
patents
HIV
Flag link:
GBT takes a page from HIV playbook as it embarks on Oxbryta launch
GBT takes a page from HIV playbook as it embarks on Oxbryta launch
Fierce Pharma
Global Blood Therapeutics
drug launches
Oxbryta
sickle cell disease
HIV
Flag link:
Gilead loses first PrEP patent challenge but vows to defend against HHS lawsuit
Gilead loses first PrEP patent challenge but vows to defend against HHS lawsuit
Fierce Pharma
Gilead Sciences
HHS
HIV
patents
PrEP
Truvada
Flag link:
US cancels trial after finding vaccine doesn't prevent HIV
US cancels trial after finding vaccine doesn't prevent HIV
BioPharma Dive
South Africa
NIH
vaccines
HIV
Flag link:
FDA Launches PEPFAR Drug Database
FDA Launches PEPFAR Drug Database
RAPS.org
FDA
PEPFAR
AIDS
HIV
Flag link:
I Have a Dream… Five Dreams for Biotech
I Have a Dream… Five Dreams for Biotech
BioSpace
biotech
patients
Alzheimer's disease
ALS
HIV
cancer
drug pricing
Flag link:

Pages